Evidence map›Paper›PMID 30034620›Full record

ArticleOncotarget2018

Region-specific alteration of histone modification by LSD1 inhibitor conjugated with pyrrole-imidazole polyamide.

Kokiladevi Alagarswamy, Ken-Ichi Shinohara, Shihori Takayanagi, Masaki Fukuyo, Atsushi Okabe, Bahityar Rahmutulla, Natsumi Yoda, Rui Qin, Naoki Shiga, Masahiro Sugiura and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. PyOpen biology · 2021
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Kokiladevi AlagarswamyDepartment of Molecular Oncology, School of Medicine, Chiba University, Chiba, Japan.
Ken-Ichi ShinoharaDepartment of Molecular Oncology, School of Medicine, Chiba University, Chiba, Japan.
Shihori TakayanagiDepartment of Pharmaceutical Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Masaki FukuyoDepartment of Molecular Oncology, School of Medicine, Chiba University, Chiba, Japan.
Atsushi OkabeDepartment of Molecular Oncology, School of Medicine, Chiba University, Chiba, Japan.
Bahityar RahmutullaDepartment of Molecular Oncology, School of Medicine, Chiba University, Chiba, Japan.
Natsumi YodaDepartment of Molecular Oncology, School of Medicine, Chiba University, Chiba, Japan.
Rui QinDepartment of Pharmaceutical Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Naoki ShigaDepartment of Pharmaceutical Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Masahiro SugiuraDepartment of Molecular Oncology, School of Medicine, Chiba University, Chiba, Japan.
Hiroaki SatoDepartment of Molecular Oncology, School of Medicine, Chiba University, Chiba, Japan.
Kazuko KitaDepartment of Molecular Oncology, School of Medicine, Chiba University, Chiba, Japan.
Takayoshi SuzukiDepartment of Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Tetsuhiro NemotoDepartment of Pharmaceutical Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Atsushi KanedaDepartment of Molecular Oncology, School of Medicine, Chiba University, Chiba, Japan.
Chiba University · JPKyoto Prefectural University of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenome regulates gene expression to determine cell fate, and accumulation of epigenomic aberrations leads to diseases, including cancer. NCD38 inhibits lysine-specific demethylase-1 (LSD1), a histone demethylase targeting H3K4me1 and H3K4me2, but not H3K4me3. In this study, we conjugated NCD38 with a potent small molecule called pyrrole (Py) imidazole (Im) polyamide, to analyze whether targets of the inhibitor could be regulated in a sequence-specific manner. We synthesized two conjugates using β-Ala (β) as a linker, i.e., NCD38-β-β-Py-Py-Py-Py (NCD38-β

Indexed as

epigenomehistone modificationlysine-specific demethylase-1 inhibitorpyrrole imidazole polyamide

Identifiers

PMID30034620
PMCPMC6047668
OpenAlexW2810005073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.